Miorexil (Thiocolchicoside)

Thiocolchicoside works by antagonizing glycine receptors in the spinal cord, which decreases inhibitory neurotransmission. This action reduces the excitability of motor neurons, leading to central muscle relaxation and relief of spasm without significant peripheral effects.

The dosage of Miorexil is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and clinical response. The prescriber will set the appropriate dose and administration schedule.

The safety of thiocolchicoside in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Miorexil, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import paperwork.

Miorexil (thiocolchicoside) differs from many other muscle relaxants by acting as a glycine‑receptor antagonist, providing central muscle relaxation without strong anticholinergic effects. Compared with agents like baclofen or tizanidine, it may have a distinct side‑effect profile and is often chosen when a different mechanism of action is desired.

Miorexil should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze the solution, and keep it out of reach of children.

Miorexil is supplied as an injectable solution for intramuscular injection. The healthcare professional administers the dose into a muscle, typically the gluteal or deltoid region, following aseptic technique and according to the prescribed regimen.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, significant liver enzyme elevations, seizures, and marked hypotension. Patients should be monitored for any signs of these reactions, and treatment should be discontinued immediately if they occur.

Miorexil should not be used by individuals with known hypersensitivity to thiocolchicoside or any excipients in the formulation. Caution is advised in patients with severe hepatic or renal impairment, and it is generally avoided in pregnant or breastfeeding women unless clearly indicated by a physician.